This review discusses the evidence in support of the use of risankizumab, its pharmacology including its mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Clinical Associate Professor Kurt Gebauer, a practicing Dermatologist with a busy private practice in Fremantle.
Please login below to download this issue (PDF)